Causes of death need confirmation

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7032.704 (Published 16 March 1996) Cite this as: BMJ 1996;312:704
  1. K A Jellinger
  1. Director Ludwig Boltzmann Institute of Clinical Neurobiology, Lainz-Hospital, A-1130 Vienna, Austria

    EDITOR,—After 5.4 years of follow up the Parkinson's Disease Research Group reports a significantly higher mortality in patients with early, mild Parkinson's disease given levodopa plus selegiline (arm 2) than in those given levodopa alone (arm 1). Although the causes of the 60% increased mortality “remain to be elucidated,” the group concludes that the data “cast doubts on the chronic use of selegiline.”1 This conclusion seems conjectural.

    Firstly, the suggested deleterious effects of selegiline on the cardiovascular system are disproved by …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription